- Conditions
- Pancreas Adenocarcinoma
- Interventions
- CPI-613® (Dose level -1.0 250 mg/m^2), CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2), CPI-613® (Dose level 3.0 1,500 mg/m^2), CPI-613® Maximum Tolerated Dose (MTD), Gemcitabine, Intensity-modulated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sarcoma, Clear Cell
- Interventions
- CPI-613 + Hydroxychloroquine
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Duarte, California • Kansas City, Kansas • Ann Arbor, Michigan + 5 more
- Conditions
- Cancer, Pancreatic Cancer, Pancreatic Carcinoma
- Interventions
- CPI-613, Gemcitabine
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Dallas, Texas
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- CPI 613, mFolfirinox, Folfirinox
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Duarte, California + 35 more
- Conditions
- Pancreatic Cancer Stage IV
- Interventions
- CPI-613, modified Folfirinox
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer
- Interventions
- CPI 613 in Combination With Gemcitabine and Nab-paclitaxel
- Drug
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Morristown, New Jersey • Summit, New Jersey
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- CPI-613, Gemcitabine, Any non-gemcitabine chemotherapies or best supportive care
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Temple, Texas
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine, Fludarabine, Cytarabine, Filgrastim
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Orange, California • San Francisco, California + 18 more
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Curosurf®, Survanta®
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 15 Minutes to 12 Hours
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Cancer
- Interventions
- CPI-613
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Advanced Cancer, Metastatic Cancer, Lymphoma, Solid Tumors, Advanced Malignancies
- Interventions
- CPI-613
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 3
- States / cities
- Peoria, Arizona • The Bronx, New York • Dallas, Texas
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- CPI-613
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Cranbury, New Jersey